

1 Early-Stage NSCLC Patients' Prognostic Prediction with Multi-information Using Transformer
2 and Graph Neural Network Model

3

4 **Authorship:** MSc Jie Lian^{1†}, MD Jiajun Deng^{2†}, Dr Sai Kam Hui³, Dr Mohamad Koohi-Moghadam⁴, Dr Yunlang
5 She², Dr Chang Chen^{2*}, Dr Varut Vardhanabhuti^{1*}

6 ¹Department of Diagnostic Radiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
7 SAR, China

8 ²Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai,
9 China

10 ³Department of Rehabilitation Science, Faculty of Health and Social Science, The Hong Kong Polytechnic
11 University, China

12 ⁴Faculty of Dentistry, The University of Hong Kong, Hong Kong SAR, China

13

14

15 ***Corresponding Authors:**

16 Varut Vardhanabhuti, MBBS BSc, FRCR, PhD

17 Clinical Assistant Professor, Department of Diagnostic Radiology, HKU

18 Mailing address: Room 406, Block K, Queen Mary Hospital, Pokfulam Road, Hong Kong SAR, China

19 Phone number: (+852) 2255 3307

20 Email: varv@hku.hk

21

22 Chang Chen, FACS, MD, PhD

23 Professor, Department of Thoracic Surgery, Tongji University School of Medicine

24 Mailing address: 507 Zhengmin Road, Shanghai, China

25 Phone number: (+86) 021-65115006

26 Email: changchenc@tongji.edu.cn

27

28 [†]These authors contributed equally to this work.

29

30 **Abstract**

31 **Background:** We proposed a population graph with Transformer-generated and clinical features for the purpose of
32 predicting overall survival and recurrence-free survival for patients with early-stage NSCLC and to compare this
33 model with traditional models.

34 **Methods:** The study included 1705 patients with lung cancer (stage I and II), and a public dataset for external
35 validation (n=127). We proposed a graph with edges representing non-imaging patient characteristics and nodes
36 representing imaging tumour region characteristics generated by a pretrained Vision Transformer. The model was
37 compared with a TNM model and a ResNet-Graph model. To evaluate the models' performance, the area under the
38 receiver operator characteristic curve (ROC-AUC) was calculated for both overall survival (OS) and recurrence-free
39 survival (RFS) prediction. The Kaplan–Meier method was used to generate prognostic and survival estimates for
40 low- and high-risk groups, along with net reclassification improvement (NRI), integrated discrimination
41 improvement (IDI), and decision curve analysis (DCA). An additional subanalysis was conducted to examine the
42 relationship between clinical data and imaging features associated with risk prediction.

43 **Results:** Our model achieved AUC values of 0·785 (95 % CI:0·716 - 0·855) and 0·695 (95 % CI:0·603 - 0·787) on
44 the testing and external datasets for OS prediction, and 0·726 (95 % CI:0·653 - 0·800) and 0·700 (95 % CI:0·615 -
45 0·785) for RFS prediction. Additional survival analyses indicated that our model outperformed the present TNM and
46 ResNet-Graph models in terms of net benefit for survival prediction.

47 **Conclusion:** Our Transformer-Graph model was effective at predicting survival in patients with early-stage lung
48 cancer, which was constructed using both imaging and non-imaging clinical features. Some high-risk patients were
49 distinguishable by using a similarity score function defined by non-imaging characteristics such as age, gender,
50 histology type, and tumour location, while Transformer-generated features demonstrated additional benefits for
51 patients whose non-imaging characteristics were non-discriminatory for survival outcomes.

52 **Funding:** There was no funding source for this study.

53 **Keywords:** Lung cancer, Graph convolutional networks, Vision Transformer, Survival Prediction

54

55

56

57 **Introduction**

58 Lung cancer is expected to account for more than 1·80 million deaths worldwide in 2021, making it the top cause of
59 cancer-related mortality ¹. In early-stage (stage I and II) non-small cell lung carcinomas (NSCLC), surgical resection
60 remains the therapy of choice. However, almost 40% to 55% of these tumours recur following surgery ². The clinical
61 care of lung cancer patients would substantially benefit from accurate prognostic evaluation. Currently, TNM staging
62 system of lung cancer based on the anatomic extent of disease is well recognised and widely adopted, which allows
63 tumours of comparable anatomic extent to be grouped together ³. Staging guides treatment and provides a broad
64 prediction of prognosis, however individual characteristics, histology, and/or therapy characteristics may impact
65 survival results, as seen by variation within stage groups. In the refinement of the staging system, non-anatomical
66 predictors such as gene mutations and biomarker profiles were proposed to be incorporated ⁴. However, the gene
67 profiling approach relies on tissue sampling, and in addition, may not fully explain the intratumoural heterogeneity
68 seen in NSCLC. Besides, such tests have barriers in deploying to routine oncology workflows due to high turnaround
69 time, complexity, and cost ⁵.

70 To predict the patient's prognosis and to optimise individual clinical management, prognostic predictors such as TNM
71 system and imaging-based high throughput quantitative biomarkers, radiomics, have been widely used to describe
72 tumours ⁶⁻¹². Artificial Intelligence (AI) methods, especially some deep learning (DL) models, have recently been
73 regarded as potentially valuable tools ¹³⁻¹⁵. DL models generated multiple quantitative assessments for tumour
74 characteristics, which have the potential to describe tumour phenotypes with more predictive power than the clinical
75 model ¹⁵. While the anatomical structures in a medical image are functionally and mechanically related, most AI-
76 based methods do not take these interdependencies and relationships into account. This leads to instability and poor
77 generalisation of performance ¹⁶. With recent advancements in AI technology, several novel models have been
78 proposed. Notably, the Transformer ¹⁷ model permits exceptional capabilities in natural language processing fields
79 such as language translation and was later applied to the computer vision field and outperformed all state-of-the-art
80 models given large amounts of training data ¹⁸. This provides an intuitive reason to apply the Transformer model to
81 the medical image to generate additional meaning for tumour features, as images were processed in sequence with
82 inherent interdependencies ¹⁹.

83 The majority of current prognostic prediction methods have focused mainly either specific to their own domains, such
84 as focusing solely on imaging data, whereas in clinical practice non-imaging clinical data such as sex, age, and disease
85 history all play critical roles in disease prognosis prediction ²⁰. Although some researchers have used multi-modal
86 techniques ²¹ to combine that information, it is not easy to explain how the various types of data interacted and how
87 they contributed to the final prediction. Due to their lack of explanatory power, those models may not be easily applied
88 in clinical practice ²². Another type of neural network, called a graph neural network (GNN) ²³, which deals with data
89 that has a graph structure, enables researchers to create more flexible ways to embed various types of data. For example,
90 nodes and edges in a graph might represent a variety of different types of data (imaging and clinical demographics
91 information), and analysing these entities reveals the role of various data sources.

92 In this study, we proposed a GNN-based model that leverages imaging and non-imaging data for the prediction of the
93 survival of patients with early-stage NSCLC. Patients were represented as a population graph, whereby each patient

94 corresponded to a graph node and was associated with a tumour feature vector that was learnt from the Transformer
95 model, and graph edge weights between patients were derived from a similarity score that was derived from
96 phenotypic data, such as demographics, tumour location, cancer type and TNM staging. This population graph was
97 used to train a GraphSAGE²⁴ model for classifying individual patient's risk of overall survival and recurrence.
98 Additionally, we attempted to determine the relative importance of imaging and non-imaging features within this
99 model. The proposed model was trained and tested on a large dataset, followed by external validation using a publicly
100 available dataset.

101 **Methods**

102 **Participants**

103 The study included consecutive patients who received surgery for early-stage NSCLC between January 2011 and
104 December 2013 who matched the criteria. Inclusion criteria included: (1) pathologically proven stage I or stage II
105 NSCLC; (2) preoperative thin-section CT image data; and (3) complete follow-up survival data. Patients undergoing
106 neoadjuvant therapy were excluded from the study. The study protocol was approved by the Shanghai Pulmonary
107 Hospital's Institutional Review Board and informed consent was waived owing to retrospective nature. Additionally,
108 patients who met our criteria were retrieved from the NSCLC Radiogenomics²⁵ dataset as an external validation set
109 (see Supplementary Figure 1 for the internal and external inclusion criteria flowchart).


110 We only used patients' initial CT scans in this study. For the main cohort, all CT scans were acquired using Somatom
111 Definition AS+ (Siemens Medical Systems, Germany) and iCT256 (Siemens Medical Systems, Germany) (Philips
112 Medical Systems, Netherlands). All image data were rebuilt using a 1 mm slice thickness and a 512×512 mm matrix.
113 Intravenous contrast was administered in accordance with institutional clinical practice. Clinical data in this study
114 were manually collected from medical records and were anonymised. Outpatient records and telephone interviews
115 were used to collect follow-up data. The period between the date of surgery and the date of death or the final follow-
116 up was defined as overall survival (OS). Recurrence-free survival (RFS) was calculated from the date of surgery to
117 the date of recurrence, death, or last follow-up. (More details about internal scan parameters and follow-up strategies
118 can be found in Supplementary II).

119 **Image Annotation and Pre-processing**

120 Patients' tumour region was manually labelled by experienced radiologists using 3D Slicer²⁶, with a centre seed point
121 defining a bounding box. The regions of interest (ROIs) were first annotated by two junior thoracic surgeons (Y.S.
122 and J.D. with 5 and 3 years of experience, respectively), then the consensus on ROI was obtained by a discussion with
123 a senior radiologist (with more than 25 years of experience).

124 For image pre-processing, we first normalised all CT images and removed the surrounding noises such as bones by
125 manual thresholding. The size of all tumour segments was fixed to 128mm × 128mm × 64mm. Small tumours were
126 zero-padded. To reduce the computational cost, we resized the padded segments into 64mm × 64mm × 36mm and
127 subsequently resized them as 2D square images (each row contained 6 tumour slices) with the size of 384mm × 384mm
128 as shown in Figure 1A.

129



130
131
132
133
134
135

Figure 1. Tumour image processing and feature generation. (A) Tumour images normalization, reshaping and padding to standard sizes, then re-arranged into 2D images, (B) Generating 1D Transformer survival features from pretrained Transformer model.

136 Tumour Transformer Feature Generator

137 When pretrained on a large dataset and transferred to image recognition benchmarks, it has been shown that Vision
138 Transformer (ViT) can achieve excellent results while requiring significantly less computational resources to train
139 than state-of-the-art convolutional models¹⁸. To this end, we reasoned that by replacing the traditional CNN feature
140 generator architecture with a Transformer structure could be an approach to produce meaningful survival-relevant
141 features. In this study, we used a ViT pretrained on a large-scale dataset (ImageNet-21k²⁷) as the feature generator,
142 which takes 2D tumour segments as inputs. To meet the standard requirements of the sequence model, the input images
143 were divided into 36 ordered patches and position embedding in the first step, followed by a linear projection function
144 before entering the Transformer Encoder. We replaced the original classification layer with a fully connected layer to
145 generate a 1D feature vector. The detailed implementation is illustrated in Figure 1B. The 1D feature vector was then
146 assigned as the node feature for the individual patient in the graph network.

147

148 Patient survival graph network

149 A population graph method was used to leverage imaging and non-imaging data. Each patient was regarded as a node
150 in a graph and its edge with neighbour was derived from a similarity score which was determined by the product
151 between 4 component scores, namely demographics (gender and age), tumour location, cancer type (histology) and
152 TNM staging (For more detail, refer to the supplementary for a detailed explanation of similarity scores). Two patients
153 would be connected to each other if they shared similar component scores. The features of an individual patient (node
154 feature) were obtained from the Transformer Encoder trained on the tumour images mentioned above.


155

156 Graph-based Neural Network Structure

157 We applied a graph-based deep neural network structure called GraphSAGE in this study. The proposed network took
158 the whole population graph, along with the edge and node features as the input and generated a risk score in the last
159 layer for each patient node as the output (see Figure 2). Within the network, every node feature was updated by an
160 aggregation of information from its neighbours and itself, while the importance of different neighbours varied by the
161 corresponding edges' weight.

162 We applied a two-layer GraphSAGE and global meaning pooling structure, aiming to allow each patient's information
163 to be updated, first from its second neighbours and then its neighbours and itself consequentially. In order to emphasise
164 the target of survival prediction, we specifically replaced the cross-entropy loss with Cox proportional hazards loss
165 function²⁸ which both considered the survival time and events when training the network. The proposed network was
166 implemented in Python, using the Deep Graph Library (DGL) with Pytorch backend.

167



168
 169 **Figure 2.** Population graph building and model prediction pipeline. (A) Each patient was regarded as a node and the
 170 Transformer-generated feature was regarded as node features. (B) Graph edges and the relevant weights were defined
 171 by their Similarity scores. (C) We then put the whole population graph to train the GraphSAGE network in order to
 172 make a prediction for each patient (pink indicates high risk and blue indicates low risk). (D) Node updating inside the
 173 GraphSAGE network.

174

175 **Statistics Analysis**

176 All patients from the main dataset were randomly separated into training, validation and testing sets with the
177 proportion of 75%, 12.5% and 12.5% separately. We also tested the model on the external validation dataset. The
178 proposed model was compared with the TNM staging system which was generally used in clinical practice and a
179 ResNet-Graph model which has the same graph structure as our proposed model while the node feature was generated
180 by a pretrained ResNet-18 model^{29,30}. Some code

181 To evaluate whether there were statistically significant variations in survival between positive and negative groups,
182 the area under the receiver operator characteristic curve (AUC) was determined for OS and RFS prediction to compare
183 the models' performance. The Kaplan–Meier (KM) method was used to generate prognostic and survival estimates for
184 groups with low and high risk (both for OS and RFS), which were stratified according to the training set's median
185 prediction probability, with the log-rank test employed to establish statistical significance. To quantify the net benefits
186 of survival prediction, we quantified the net reclassification improvement (NRI) and integrated discrimination
187 improvement (IDI), as well as performed a decision curve analysis. All of the analyses above were performed in
188 Python using the Lifelines package.

189 An additional subanalysis was performed on the test dataset to explore the relationship between patients' clinical
190 information and imaging features contributing to risk prediction. We generated a sub-graph visualisation using PyVis
191 and a KM analysis was used for several subgraphs to evaluate our model's ability to separate high-risk patients. Finally,
192 as a proof of concept, we plotted one patient's node feature changes before and after 1 layer processing using a
193 correlation heatmap, along with its neighbours' edge weights analysis to try to understand the inner workings of our
194 model.

195

196 **Results**

197 **Data Description**

198 In the main cohort, we initially enrolled 2309 patients and after exclusion based on our criteria, a total of 1705 NSCLC
199 patients were included in the study. The median age was 61 (interquartile range, 55-66 years). There were 1010 males
200 (59.2%) and 695 women (40.8%). Tumours were more frequently located in the upper lobes (1018, 59.7%). A total
201 of 1235 patients (72.4%) had adenocarcinoma, while 391 patients (22.9%) had squamous cell carcinoma. The
202 distribution of pathologic stages was as follows: stage IA was present in 791 patients (46.4%), stage IB was present
203 in 607 patients (35.6%), stage IIA was present in 133 patients (7.8%), and stage IIB was present in 174 patients
204 (10.2%). The OS and RFS rates were 78.2 % (95% CI: 76.2% - 80.2%) and 74.2 % (70.8% -77.6%), respectively.
205 The external validation dataset included a total of 127 patients of which 32 (25.2%) were females and 95 (74.8%)
206 males, with a median age of 69 (interquartile range, 46-87 years). Upper lobe tumours were also more prevalent (76
207 patients, 59.8%). Among them were 95 patients diagnosed with adenocarcinoma and 30 with squamous cell
208 carcinoma. The OS and RFS rates were 68.5 % (95% CI: 60.4 % - 77.7 %) and 59.1 % (95% CI: 50.4 % -67.8 %),
209 respectively. Please refer to Table 1 for more detailed information.

210

211 Table 1: Feature distribution in the total patient cohorts, training and validation cohorts and the test cohorts

		TRAIN and VAL (n = 1492)	TEST (n = 213)		EXTERNAL (n= 127)	
Feature	Content	Mean, SD, 95% CI / Count, %		P	Mean, SD, 95% CI / Count, %	P
Age	Age	60·6, 8·7, (CI: 60·1, 61·0)	60·7, 9·5, (CI: 59·4, 62·0)	> 0·05	68·7, 9·1, (CI: 67·2, 70·1)	< 0·01**
Sex	Female No. (%); Male No. (%)	602 (33·3); 890 (66·7)	93 (33·3); 120 (66·7)	>0·05	32 (25·2); 95 (74·8)	< 0·01**
Resection	Sublobar Resection No. (%); Lobectomy No. (%); Bilobectomy No. (%); Pneumonectomy No. (%)	123 (8·2); 1292 (86·6); 59 (3·95); 18 (1·2)	23 (10·8); 180 (84·5); 7 (3·3); 3 (1·4)	> 0·05	/	/
Histology	Adenocarcinoma No. (%); Squamous Cell Carcinoma No. (%); Others No. (%)	1072 (71·4); 351 (23·5); 69 (4·6)	163 (76·5); 40 (18·8); 10 (4·7)	> 0·05	95 (74·8); 30 (23·6); 2 (1·6)	> 0·05
Tumour Location	LUL No. (%); LLL No. (%); RUL No. (%); RML No. (%); RLL No. (%)	384 (25·7); 211 (14·1); 504 (33·8); 146 (9·8); 247 (16·6)	51 (23·9); 37 (17·4); 79 (37·1); 15 (7·0) 31 (14·6)	>0·05	30 (23·6); 22 (17·3); 46 (36·2); 15 (11·8); 14 (11·0).	>0·05
Tumour Size	Tumour Size	2·68, 1·38, (CI: 2·61, 2·75)	2·55, 1·25, (CI: 2·38,2·71)	> 0·05	/	/
pTNM stage	Stage I No. (%); Stage II No. (%);	1219 (81·7); 273 (18·3)	179 (84·0); 34 (16·0)	> 0·05	97 (76·3); 30 (23·7)	< 0·01**
RFS Status	RFS No. (%)	1089 (73·0)	154 (72·3)	> 0·05	75 (59·1)	> 0·05
RFS Month	RFS Month	57·5, 24·5, (CI: 56·2, 58·7)	58·4, 23·4, (CI: 55·2, 61·5)	> 0·05	39·5, 26·9, (CI: 34·8, 44·2)	< 0·01**
OS Status	OS No. (survival %)	1166 (78·2)	167 (78·4)	> 0·05	87 (68·5)	>0·05
OS Month	OS Month	62·4, 19·9, (CI: 61·4, 63·4)	63·4, 18·4, (CI: 60·9, 65·9)	> 0·05	44·8, 27·8, (CI:40·9, 50·0)	< 0·01**

212

213

214 Model performance

215 To develop deep transformer graph learning–based biomarkers for overall survival prediction, we trained on the main
216 cohorts, separated into training and validation datasets and then evaluated them separately on the testing set (213
217 patients) and the external set (127 patients). For OS prediction, our model achieved AUC values of 0.785 (95 %
218 CI:0.716 - 0.855) and 0.695 (95 % CI:0.603 - 0.787) on the testing and external datasets, respectively, compared to
219 0.690 (95 % CI:0.600 - 0.780) and 0.634 (95 % CI: 0.544 - 0.724) for the TNM model, and 0.730 (95 % CI:0.640 -
220 0.820) and 0.626 (95 % CI:0.530 – 0.722) for ResNet-Graph model. For RFS prediction, our model achieved AUC
221 values of 0.726 (95 % CI:0.653 - 0.800) and 0.700 (95 % CI:0.615 - 0.785) on the testing and external datasets,
222 respectively, compared to 0.628 (95 % CI:0.542 - 0.713) and 0.650 (95 % CI: 0.561 - 0.732) for the TNM model,
223 and 0.681 (95 % CI:0.598 - 0.764) and 0.595 (95 % CI:0.615 – 0.785) for ResNet-Graph model (Figure 3A and 3B).
224 Additional survival analyses were performed using KM estimates for groups with low and high risk of mortality and
225 recurrence, respectively, based on the median stratification of patient prediction scores (Figure 3C and 3D). All three
226 models showed statistically significant differences in 5-year overall survival. For RFS prediction, the ResNet-Graph
227 model was unable to distinguish between individuals at low and high risk ($p > 0.05$), while both Transformer-Graph
228 and TNM models were able to separate high and low risk of recurrence-free survival groups ($p < 0.05$). Additionally,
229 the decision curve analysis (Figure 3E) and net benefit analysis (IDI, NRI) indicated that the Transformer-Graph
230 model significantly outperformed the present TNM and ResNet-Graph models in terms of net benefit for both OS and
231 RFS survival prediction.

232 As for detailed net benefit analysis, Transformer-Graph model outperformed the present TNM and ResNet-Graph
233 models in terms of IDI and NRI. Our proposed model improved the survival prediction significantly compared with
234 TNM regarding NRI (OS: 0.284, 95% CI: -0.112-0.519, $p < 0.0001$; RFS:0.175, 95% CI:-0.115 - 0.486, $p < 0.0001$)
235 and IDI (OS:0.159, 95% CI: 0.103-0.214, $p = 0.00032$; RFS:0.137, 95% CI: 0.086-0.189, $p = 0.00074$). The results
236 comparing with ResNet-Graph were reported in Supplementary IV.


237 Patients' clinical-based graph analysis

238 We visualised the whole internal set (Figure 4A) along with the testing cohorts subplot (Figure 4B) and analysed two
239 challenging cases to better understand the population-based graph structure and how clinical data was integrated with
240 node attributes (i.e. patients' tumour images). The testing subplot showed that while the graph structure (specified by
241 the similarity score) was capable of broadly separating at-risk patients, several clusters had both high- and low-risk
242 patients intermingled together, making them difficult to separate using traditional clinical information (see Figure 4C
243 and 4D). The subsequent KM analysis indicated that by using Transformer-generated tumour attributes, high- and
244 low-risk patients could be significantly discriminated.

245 Additionally, we analysed specifically as an example, patient No 44, and surrounding neighbours' edge weights
246 distribution, as well as the initial and subsequent 1 layer node features. This patient was a high-risk patient who died
247 after 38 months, with 42 neighbours. Initially, we analysed the correlation coefficient between neighbours' node
248 features in order to determine the role that transformer-generated image features played prior to graph training. As

249

250



251
252
253
254
255
256

Figure 3. Model Performance: (A) ROC-AUC curve on test data and external set for OS and (B) RFS prediction and (C) KM curve on test data set for OS and (D) RFS prediction. (E) Decision curve on test data set for OS and RFS prediction.


257 illustrated in Figure 4E, the correlation matrix of Transformer-generated features revealed that almost all of patient
258 No. 44's high-risk (dashed box nodes) and low-risk neighbours were highly correlated, implying that image features
259 did not contain directly discriminative survival information before learning. We next then examined the distribution
260 of neighbours' edge weights. As illustrated in Figure 4E, despite the fact that there were only five high-risk
261 neighbours, the median value of similarity scores was slightly higher than that of low-risk neighbours (2.50 vs
262 2.00), indicating that the high-risk neighbour group was more closely connected to the target nodes from non-
263 imaging information aspects.

264 After one layer of GraphSAGE updating, we discovered that the high-risk neighbours were more correlated with
265 patient No. 44 (see Figure 4E GraphSAGE Layer 1, nodes in the dash boxes showed higher coefficient values),
266 revealing that within our model, both neighbours' nodes and edge features contained survival-related information,
267 and they contributed together to efficiently provide information for the target node learning.

268 **Discussion**

269 We demonstrated the feasibility of using Vision Transformer on CT images of the lung tumours to generate features
270 for cancer survival analysis in this study. Additionally, we used a graph structure to embed patients' imaging and non-
271 imaging clinical data separately in the graph neural network and attempted to explain how clinical data communicates
272 with Transformer-generated imaging features for survival analysis. While Transformer and GNN models have been
273 widely used in computer vision, their application in the medical field, particularly for survival prediction, is still
274 evolving due to the complexity and unbalanced nature of medical data (high dimension, multiple data formats,
275 including non-imaging data). In our study, we combined these two methods and created a specially designed graph
276 structure to handle a variety of data formats, demonstrating the utility of Transformer-generated features in survival
277 analysis and emphasizing the extent to which clinical data and imaging features contribute to the prediction. To our
278 knowledge, this is the first work to demonstrate the feasibility of using Transformer in survival prediction using a
279 graph data structure and exploratory analysis of the models' intuitions in an attempt to explain these state-of-the-art
280 methods.

281 Our experiments indicated that the proposed model outperformed the commonly used TNM model in predicting
282 survival not only on the testing dataset but also on the external dataset, despite the fact that the data distributions were
283 significantly different (refer to Table 1, the survival distribution on the external dataset is significantly different from
284 the internal dataset), demonstrating the model's generalisability for unseen data. The model's good performance
285 indicated that both the Transformer-generated imaging features and the structure of our population graph (i.e., using
286 graph edges and nodes to combine non-imaging clinical data and imaging data) contained useful information for
287 survival. Additionally, the subplot graph on the testing dataset (Figure 4B) indicated that our graph structure was
288 capable of approximate clustering high- and low-risk groups and segregating the majority of the high-risk patients.
289 Meanwhile, when patients were similar in terms of demographic information and it was hard to determine the risk
290 patients by traditional clinical methods (refer to Figures 4C and 4D the dense graphs containing both pink and blue
291 nodes), the Transformer-generated image features and edge weights had more roles to play in determining the
292



293
294
295
296
297
298
299
300
301

Figure 4. Testing set graph analysis. (A) A visual representation of the whole cohort population graph of 1705 patients. (B) A visual representation of the testing sub-graph of 213 patients. (C) and (D) Two subgraphs containing challenging cases where the graphs contained both high- and low-risk patients. (E) Node features' correlation heatmaps and edge weights distribution of patient No. 44: Each square represents a neighbour's node features' correlation coefficient, higher values (red colour) reveal closer relation with the target node; The box plot of 42 neighbours indicates that the high-risk neighbours (blue box) have higher edge weights median.

302 differences between neighbours. More specifically, the Transformer-generated features did not contain directly
303 discriminative survival information before learning, while with edge weights together, effective information from with
304 neighbours' node features could be passed. In this case, all patient's node features could be effectively updated, and
305 high-risk patients could be better discriminated as in Figure 4E.

306
307 Our study contains several strengths. First, our dataset is relatively large, encompassing both contrast and non-contrast
308 CT. This not only aided in the model's generalisation learning but also allows for flexibility in the imaging standards
309 in clinical settings. Second, our graph model demonstrated the ability to combine non-imaging clinical features with
310 imaging features in an understandable manner, implying a new direction of embedding multi-data with deep learning
311 models. Finally, we sought to understand the roles of imaging and non-imaging features in determining high-risk
312 nodes within the graph neural network, which could aid clinicians in comprehending the internal workings of the
313 neural networks.

314
315 There are some limitations worth noting. First, whilst the proposed model significantly outperformed the TNM model
316 on the external dataset (OS prediction AUC 0.693 vs 0.633, RFS prediction RFS 0.700 vs 0.650), the model's
317 performance on the external set was below that of the testing set (AUC 0.783 and 0.726 for OS and RFS). One reason
318 could be that the patients' demographics were different, particularly in terms of age (the external group's average age
319 was ten years older than the main cohort), cancer staging (84.0 % stage I in the main cohort while 76.3 % in the
320 external testing set), and gender (male percentage 66.7 % vs 78.3 %). Given the fact that the two datasets originate
321 from distinct countries, as well as the differences in ethnicity, treatment and follow-up strategies (see Table 1,
322 especially the mean follow-up time) may also have an impact on the prediction performance. Second, the initial step
323 requires the human observer to identify the tumour and draw a bounding box which in our study was still a manual
324 procedure. As the pipeline for automatic tumour detection and segmentation becomes more mature, this step can
325 potentially be automated allowing for ease of translation into the clinics.

326
327 In conclusion, the population graph deep learning model constructed using Transformer-generated imaging and non-
328 imaging clinical features was proven to be effective at predicting survival in patients with early-stage lung cancer. The
329 subanalysis concluded that by developing a meaningful similarity score function and comparing patients' non-imaging
330 characteristics such as age, gender, histology type, and tumour location, the majority of high-risk patients can already
331 be separated. Additionally, when high- and low-risk patients shared very similar demographic information, TNM
332 information provided additional information for survival prediction when combined with tumour imaging features.

333
334

335 **Conflict of interest statements**

336 All authors declare no competing interests.

337

338 **Data Availability**

339 The current manuscript is a computational study, so no data have been generated for this manuscript.

340

341 **Code Availability**

342 To aid reproducibility of research, our codes are published on the Github repository:

343 <https://github.com/SereneLian/TransGNN-Lung>

344

345

346 Reference


- 347 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. *CA Cancer J Clin.* Jan 2021;71(1):7-
348 33. doi:10.3322/caac.21654
- 349 2. Ambroggi MC, Fanucchi O, Cioni R, et al. Long-term results of radiofrequency ablation treatment of stage I
350 non-small cell lung cancer: a prospective intention-to-treat study. *Journal of Thoracic Oncology.* 2011;6(12):2044-
351 2051.
- 352 3. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision
353 of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. *Journal*
354 *of Thoracic Oncology.* 2016;11(1):39-51.
- 355 4. Giroux DJ, Van Schil P, Asamura H, et al. The IASLC lung cancer staging project: a renewed call to
356 participation. *Journal of Thoracic Oncology.* 2018;13(6):801-809.
- 357 5. Malone ER, Oliva M, Sabatini PJ, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies.
358 *Genome medicine.* 2020;12(1):1-19.
- 359 6. Du R, Lee VH, Yuan H, et al. Radiomics model to predict early progression of nonmetastatic
360 nasopharyngeal carcinoma after intensity modulation radiation therapy: a multicenter study. *Radiology: Artificial*
361 *Intelligence.* 2019;1(4):e180075 2638-6100.
- 362 7. Aonpong P, Iwamoto Y, Wang W, Lin L, Chen Y-W. Hand-Crafted and Deep Learning-Based Radiomics
363 Models for Recurrence Prediction of Non-Small Cells Lung Cancers. *Innovation in Medicine and Healthcare.*
364 Springer; 2020:135-144.
- 365 8. Bera K, Braman N, Gupta A, Velcheti V, Madabhushi A. Predicting cancer outcomes with radiomics and
366 artificial intelligence in radiology. *Nature Reviews Clinical Oncology.* 2021:1-15.
- 367 9. Carmody DP, Nodine CF, Kundel HL. An analysis of perceptual and cognitive factors in radiographic
368 interpretation. *Perception.* 1980;9(3):339-344.
- 369 10. Chirra P, Leo P, Yim M, et al. Multisite evaluation of radiomic feature reproducibility and discriminability
370 for identifying peripheral zone prostate tumors on MRI. *Journal of Medical Imaging.* 2019;6(2):024502.
- 371 11. Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, van Beek E, Jr. The 7th lung cancer TNM classification and
372 staging system: Review of the changes and implications. *World J Radiol.* 2012;4(4):128-134.
373 doi:10.4329/wjr.v4.i4.128
- 374 12. van Griethuysen JJM, Fedorov A, Parmar C, et al. Computational Radiomics System to Decode the
375 Radiographic Phenotype. *Cancer research.* 2017;77(21):e104-e107. doi:10.1158/0008-5472.CAN-17-0339
- 376 13. Chilamkurthy S, Ghosh R, Tanamala S, et al. Deep learning algorithms for detection of critical findings in
377 head CT scans: a retrospective study. *The Lancet.* 2018;392(10162):2388-2396. doi:10.1016/S0140-6736(18)31645-
378 3

- 379 14. Nabulsi Z, Sellergren A, Jamsy S, et al. Deep learning for distinguishing normal versus abnormal chest
380 radiographs and generalization to two unseen diseases tuberculosis and COVID-19. *Scientific Reports*. 2021/09/01
381 2021;11(1):15523. doi:10.1038/s41598-021-93967-2
- 382 15. Xu Y, Hosny A, Zeleznik R, et al. Deep Learning Predicts Lung Cancer Treatment Response from Serial
383 Medical Imaging. *Clin Cancer Res*. 2019;25(11):3266-3275. doi:10.1158/1078-0432.CCR-18-2495
- 384 16. Zhou SK, Greenspan H, Davatzikos C, et al. A review of deep learning in medical imaging: Imaging traits,
385 technology trends, case studies with progress highlights, and future promises. *Proceedings of the IEEE*. 2021;
- 386 17. Vaswani A, Shazeer N, Parmar N, et al. Attention is all you need. 2017:5998-6008.
- 387 18. Dosovitskiy A, Beyer L, Kolesnikov A, et al. An image is worth 16x16 words: Transformers for image
388 recognition at scale. *arXiv preprint arXiv:201011929*. 2020;
- 389 19. Zhou L, Liu H, Bae J, He J, Samaras D, Prasanna P. Self Pre-training with Masked Autoencoders for
390 Medical Image Analysis. *arXiv preprint arXiv:220305573*. 2022;
- 391 20. Holzinger A, Haibe-Kains B, Jurisica I. Why imaging data alone is not enough: AI-based integration of
392 imaging, omics, and clinical data. *European Journal of Nuclear Medicine and Molecular Imaging*.
393 2019;46(13):2722-2730.
- 394 21. Xue Y, Xu T, Long LR, et al. Multimodal recurrent model with attention for automated radiology report
395 generation. Springer; 2018:457-466.
- 396 22. London AJ. Artificial intelligence and black-box medical decisions: accuracy versus explainability.
397 *Hastings Center Report*. 2019;49(1):15-21.
- 398 23. Kipf TN, Welling M. Semi-supervised classification with graph convolutional networks. *arXiv preprint*
399 *arXiv:160902907*. 2016;
- 400 24. Hamilton WL, Ying R, Leskovec J. Inductive representation learning on large graphs. presented at:
401 Proceedings of the 31st International Conference on Neural Information Processing Systems; 2017; Long Beach,
402 California, USA.
- 403 25. Bakr S, Gevaert O, Echegaray S, et al. A radiogenomic dataset of non-small cell lung cancer. *Scientific*
404 *data*. 2018;5(1):1-9.
- 405 26. Fedorov A, Beichel R, Kalpathy-Cramer J, et al. 3D Slicer as an image computing platform for the
406 Quantitative Imaging Network. *Magnetic resonance imaging*. 2012;30(9):1323-1341.
- 407 27. Ridnik T, Ben-Baruch E, Noy A, Zelnik-Manor L. Imagenet-21k pretraining for the masses. *arXiv preprint*
408 *arXiv:210410972*. 2021;
- 409 28. Katzman JL, Shaham U, Cloninger A, Bates J, Jiang T, Kluger Y. DeepSurv: personalized treatment
410 recommender system using a Cox proportional hazards deep neural network. *BMC medical research methodology*.
411 2018;18(1):1-12.

- 412 29. Khanna A, Londhe ND, Gupta S, Semwal A. A deep Residual U-Net convolutional neural network for
413 automated lung segmentation in computed tomography images. *Biocybernetics and Biomedical Engineering*.
414 2020/07 2020;40(3):1314-1327. doi:10.1016/j.bbe.2020.07.007
- 415 30. Chen S, Ma K, Zheng Y. Med3D: Transfer Learning for 3D Medical Image Analysis.
416 2019:arXiv:1904.00625. Accessed April 01, 2019. <https://ui.adsabs.harvard.edu/abs/2019arXiv190400625C>
417
418

419 Supplementary I

420



421

422 Supplementary Figure 1: Overall flow of the study in both internal and external dataset

423

424

425 [Supplementary II Scanner parameter and follow-up strategies](#)

426 CT scans ranged from thoracic inlet to subcostal plane and were obtained before surgical resection from 2 CT
427 machines: Brilliance (Philips Medical Systems Inc, Cleveland, OH) and SOMATOM Definition AS (Siemens
428 Aktiengesellschaft, Munich, Germany).

429 CT parameters of Brilliance (Philips Medical Systems Inc) were as follows: 64 x 1 mm acquisition; 0.75-second
430 rotation time; slice width 1 mm; tube voltage, 120 kVp; tube current, 150 to 200 mA; lung window center: -700
431 Hounsfield units (HU), and window width: 1200 HU; mediastinal window center: 60 HU and window width: 450
432 HU level; pitch: 0.906; and field of view (FOV): 350 mm.

433 CT parameters of the SOMATOM Definition AS (Siemens Aktiengesellschaft) were as follows: 128 x 1 mm
434 acquisition; 0.5-second rotation time; slice width: 1 mm; tube voltage: 120 kVp; tube current: 150 to 200 mA; lung
435 window center: -700 HU and window width 1200 HU; and mediastinal window center: 60 HU and window width:
436 450 HU level; FOV: 300 mm; pitch: 1.2; and FOV: 350 mm. CT images were reconstructed into 0.67- to 1.25-mm
437 section thicknesses according to a high-resolution algorithm.

438 Follow-up was conducted through outpatient examinations or telephone calls.

439 Chest CT scan and abdominal ultrasound/CT were performed on follow-up visits within a duration of 3, 6, and 12
440 months after operation and annually thereafter for 5 years. Magnetic resonance imaging for brain and bone scan
441 were annually performed for 5 years or when the patient had signs or symptoms of recurrence.

442

443 [Supplementary III Similarity Score Definition](#)

444 Similarity score for patient x and patient y :

445
$$Sim(x, y) = C_{xy} * L_{xy} * H_{xy} * T_{xy}$$

446 C_{xy} : if x and y have same gender, get 1 point; if x and y 's age difference is within 5 year, get another 1 point.

447 L_{xy} : if x and y 's tumours locate at the same lung lobes, get 1 point.

448 H_{xy} : if x and y 's histology of tumours is the same type, get 1 point.

449 T_{xy} : if x and y have the same T stage, get 1 point; if x and y have the same N stage, get another point; if x and y
450 have the same M stage, get another 1 point.

451

452 When $Sim(x, y) > 0$, patient x and y can be connected.

453

454 [Supplementary IV: ResNet-Graph NRI and IDI results](#)

455 Transformer-Graph comparing with ResNet-Graph, regarding NRI (OS:0.240, 95% CI: -0.325-0.600, $P < .001$; RFS:
456 0.104, 95% CI: -0.41-0.389, $P < .001$) and IDI (OS:0.075 , 95% CI: 0.068 – 0.082 , $P < .05$; RFS: 0.063, 95% CI:
457 0.027 -0.098, $P < .05$).